Zoetis Inc. (ZTS): Results of Operations and Financial Condition
Zoetis Inc. (ZTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Zoetis Announces Second Quarter 2026 Results • Revenue Flat at $2.5 Billion and Net Income of $691 Million, or $1.65 per Diluted Share, Decreasing 5% and Increasing 1%, Respectively, on a Reported Basis • Adjusted Net Income of $781 Million, or Adjusted Diluted EPS o
How this was made
The 30-second read
Why it matters
The key tradable element is the full-year 2026 guidance revision: organic operational revenue growth (3)% to (1)% and adjusted net income organic operational growth (9)% to (5)%, alongside adjusted diluted EPS of $6.15-$6.25.
Market read
This is a primary earnings-and-guidance disclosure with explicit downside revisions, plus segment-level detail that can drive model changes and near-term positioning.
What to watch
US revenue fell 7% while International grew 6% organically; traders may be underweighting FX/geography mix and the potential for livestock and diagnostics to offset companion animal pressure.
Revenue Flat at $2.5 Billion and Net Income of $691 Million, or $1.65 per Diluted Share, Decreasing 5% and Increasing 1%, Respectively, on a Reported Basis
Second-quarter revenue was flat and declined 1% on an organic operational basis, as a 7% decline in the U.S. segment offset 8% reported growth internationally. Adjusted net income and adjusted diluted EPS remained positive but declined 1% and rose 5%, respectively, on a reported basis, while full-year revenue and adjusted net income guidance call for organic operational declines.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| RevenueGAAP | $2.5 billion | – | flat |
| Revenue organic operational changenon-GAAP | decreasing 1% | – | decreasing 1% |
| Net incomeGAAP | $691 million | – | decreasing 5% |
| Diluted EPSGAAP | $1.65 per diluted share | – | increasing 1% |
| Adjusted net incomenon-GAAP | $781 million | – | decreasing 1% |
| Adjusted net income organic operational changenon-GAAP | decreasing 2% | – | decreasing 2% |
| Adjusted diluted EPSnon-GAAP | $1.87 per diluted share | – | increasing 5% |
| Adjusted diluted EPS organic operational changenon-GAAP | increasing 4% | – | increasing 4% |
| Adjusted net income exclusionsnon-GAAP | $90 million | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| United States (U.S.)Companion animal product sales decreased 11% due to continued softer end-market demand, price sensitivity, heightened competition, generic competition on Cerenia and Convenia, and lower Librela sales. Livestock product sales increased 23%, supported by cattle and poultry. | $1.3 billion | – | decreasing 7% on both a reported and an organic operational basis |
| InternationalCompanion animal growth was led by parasiticides including Simparica Trio, Revolution and Stronghold, diagnostics, and OA pain launches. Livestock growth was driven by cattle and poultry. | $1.2 billion | – | increasing 8% on a reported basis and 6% on an organic operational basis |
Full Year 2026 outlook
- Revenue$9.120 billion to $9.320 billion
- NoteOrganic operational revenue growth of (3)% to (1)%
- NoteReported net income of $2.330 billion to $2.380 billion
- NoteAdjusted net income of $2.570 billion to $2.620 billion
- NoteAdjusted net income organic operational growth of (9)% to (5)%
- NoteReported diluted EPS of $5.55 to $5.65
- NoteAdjusted diluted EPS of $6.15 to $6.25
- NoteThis guidance reflects foreign exchange rates as of July 21, 2026.
What drove it
- U.S. livestock product sales increased 23% on both a reported and organic operational basis, supported by strength across cattle and poultry.
- International companion animal sales grew 8% on a reported basis and 5% on an organic operational basis, led by parasiticides, diagnostics, and OA pain products.
- In July, Zoetis completed the acquisition of VitalRADS, a veterinary teleradiology services platform.
- Lenivia and Portela launched in Canada and the EU and were approved in Great Britain. Lenivia was also approved in Switzerland.
- Poulvac Procerta HVT-ND received marketing authorization from the European Commission in July.
Concerns
- U.S. companion animal product sales decreased 11% due to continued softer end-market demand.
- The dermatology franchise and Simparica Trio faced macro-driven price sensitivity and heightened competitive pressure.
- Generic competition affected Cerenia and Convenia, and Librela sales were lower.
- International growth was partially offset by lower sales of key dermatology products and challenging market conditions impacting the broader portfolio.
- Full-year guidance calls for organic operational revenue growth of (3)% to (1)% and adjusted net income organic operational growth of (9)% to (5)%.
What to watch
- Execution of targeted investments, innovation, and business development initiatives in response to pressured companion animal market conditions.
- Demand trends for U.S. companion animal products, including the dermatology franchise, Simparica Trio and Librela.
- The durability of livestock growth in cattle and poultry across the U.S. and International segments.
- Growth contribution from international parasiticides, diagnostics, Lenivia and Portela.
- Integration of VitalRADS and the expansion of Zoetis' Global Diagnostics and Virtual Reference Lab capabilities.
Analysis
Zoetis reported second-quarter 2026 revenue of $2.5 billion, flat compared with the second quarter of 2025 and decreasing 1% on an organic operational basis. Reported net income was $691 million, decreasing 5%, while diluted EPS was $1.65 per diluted share, increasing 1%. Adjusted net income was $781 million, decreasing 1% on a reported basis and decreasing 2% on an organic operational basis. Adjusted diluted EPS was $1.87 per diluted share, increasing 5% on a reported basis and increasing 4% on an organic operational basis.
The geographic mix was sharply divergent. U.S. revenue totaled $1.3 billion and decreased 7% on both a reported and organic operational basis. U.S. companion animal product sales decreased 11%, reflecting softer end-market demand, lower clinic visits, pet owner price sensitivity, heightened competition, generic competition on Cerenia and Convenia, and lower Librela sales. This was partly countered by U.S. livestock product sales growth of 23%, supported by cattle and poultry.
International revenue totaled $1.2 billion, increasing 8% on a reported basis and 6% on an organic operational basis. International companion animal product sales grew 8% on a reported basis and 5% on an organic operational basis, led by parasiticides, diagnostics, and OA pain products. International livestock product sales grew 8% on a reported basis and 6% on an organic operational basis, driven by cattle and poultry. The release also identifies lower dermatology sales and challenging broader market conditions as offsets to International growth.
Management is continuing to invest in product approvals, launches and diagnostics capabilities. During the quarter and subsequent July activity described in the release, Zoetis advanced Poulvac Procerta HVT-ND, expanded Lenivia and Portela access, and completed the acquisition of VitalRADS. The company said its pipeline includes more than 12 potential blockbuster candidates. These initiatives are positioned as efforts to expand companion animal therapeutics and diagnostics while responding to disease threats affecting livestock.
The updated full-year 2026 outlook reflects the current operating environment. Zoetis guided to revenue of $9.120 billion to $9.320 billion, with organic operational revenue growth of (3)% to (1)%, and adjusted net income organic operational growth of (9)% to (5)%. The company also guided to reported net income of $2.330 billion to $2.380 billion, adjusted net income of $2.570 billion to $2.620 billion, reported diluted EPS of $5.55 to $5.65, and adjusted diluted EPS of $6.15 to $6.25. The guidance reflects foreign exchange rates as of July 21, 2026.
Management, verbatim
Second quarter results reflected a more pressured Companion Animal market, as lower clinic visits and pet owner price sensitivity reduced demand across parts of our portfolio and heightened competition in key categories.
Kristin Peck, Chief Executive Officer
At the same time, these dynamics reinforce the enduring attractiveness of the markets Zoetis has helped define and advance.
Kristin Peck, Chief Executive Officer
We are adapting our commercial strategy to the marketplace in front of us, deploying targeted investments, accelerating innovation, and pursuing business development to strengthen our position in areas aligned with the future of animal health.
Kristin Peck, Chief Executive Officer
Not in the filing
stated, not guessed- Period-end date
- Prior-year revenue amount
- Prior-quarter revenue amount and comparison
- Prior-year and prior-quarter net income amounts
- Prior-year and prior-quarter diluted EPS amounts
- Prior-year and prior-quarter adjusted net income amounts
- Prior-year and prior-quarter adjusted diluted EPS amounts
- Gross profit and gross margin
- Operating income and operating margin
- Operating expenses
- Operating cash flow
- Free cash flow
- Cash and cash equivalents
- Debt
- Share repurchases
- Dividends
- Prior full-year guidance for comparison
- Segment prior-year revenue amounts
- Segment prior-quarter revenue amounts
- Exact prior-year amounts for U.S. companion animal and livestock product sales
- Exact prior-year amounts for International companion animal and livestock product sales
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Zoetis filed an SEC 8-K (Item 2.02) with Exhibit 99.1 covering Q2 2026 financial results, segment performance, and multiple regulatory/product updates.
Ticker impact
Zoetis reported Q2 2026 results and revised full-year 2026 revenue guidance to $9.120-$9.320B and adjusted EPS to $6.15-$6.25.
Likely near-term downside bias as traders reprice full-year organic growth and adjusted EPS expectations; volatility possible around the guidance range.
The filing is a primary disclosure (8-K with Exhibit 99.1) containing fresh quarterly datapoints and explicit full-year guidance revisions, which typically drive earnings-model updates and positioning.
Market effects
Animal health peers may see read-across on companion animal demand softness and generic-competition impacts, while livestock strength could support selective optimism.
US segment weakness versus International growth may shift regional allocation and expectations for future product mix.
EU/UK approvals and US screwworm response highlight ongoing regulatory momentum, but near-term financial guidance dominates sentiment.
Counterpoint
Despite weaker guidance, the company cites a pipeline with more than 12 potential blockbusters and ongoing major-market approvals, which could limit long-term downside if investors overreact to one-year organic softness.
Key entities
- companyZoetis Inc.
Animal health company reporting Q2 2026 results and revising full-year 2026 revenue and adjusted EPS guidance.
- executiveKristin Peck
CEO quoted attributing pressure to softer companion animal clinic visits, price sensitivity, and heightened competition.
